The company said, "Aiming to drive growth for our commercial drug, Danyelza in the U.S. through market growth and potential label expansion to target an estimated U.S. market opportunity of $400M for high-risk neuroblastoma and osteosarcoma alone. Seeking initial validation of the tumor binding capability of our novel SADA platform in solid tumors in the GD2-SADA multicenter trial through the collection of imaging data in patients with small-cell lung cancer, sarcoma, and malignant melanoma. Targeting an IND submission in Q2 2023 for CD38-SADA construct against non-Hodgkin’s lymphoma to potentially validate SADA in blood cancers. Seeking partnerships based on the SADA technology platform. Discussing potential regulatory pathway for omburtamab at Type A meeting with the FDA."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on YMAB:
- Y-mAbs Announces Restructuring Plan and Provides Financial Outlook Following Complete Response Letter from FDA
- Y-mAbs Therapeutics enters distribution agreement with WEP Clinical
- The CHMP has Adopted a Negative Opinion for Omburtamab for the Treatment of CNS/LM Metastasis from Neuroblastoma in Europe
- Y-mAbs Announces Pipeline Update
- Y-mAbs Therapeutics announces pipeline updates
